Products




1 - Preventing the spread of drug-resistant bacteria : Rapid molecular assays

BD MAX™ Enteric Bacterial     BD MAX™ Enteric Bacterial

Brochure

 

Introducing the first panel in the BD MAX portfolio for Enteric Solutions!

 

Salmonella spp. – Shigella spp. – Campylobacter spp. (jejuni and coli) Shiga toxin-producing E. coli (STEC) 

The Challenge

Hospitals and laboratories are faced with increasing challenges in managing clinician and patient needs. In the microbiology laboratory, diagnosing gastroenteritis caused by bacteria is demanding as the stool bench requires a high level of technologist expertise and labor with multiple testing methods extending the time to result up to 4 days or more.

Clinicians require these results in a more rapid time frame in order to accurately manage patients suffering from disease caused by these bacteria. In patients with STEC, administering antimicrobial therapy is contra-indicated and may cause adverse reactions, increasing the risk of hemolytic uremic syndrome (HUS) which can have a high mortality rate.

The Solution

BD MAX Enteric Bacterial Panel provides results in <3 hours once the specimen is loaded into the system. In the laboratory, the reduction of multiple methods, expertise and labor required to perform testing is achieved.

 

The BD MAX Enteric Bacterial Panel detects approximately 95% of bacteria causing infectious gastroenteritis.

Compared to conventional stool culture methods:

  • Reduces materials on average by 60%
  • Saves space and resources required for culture
  • Eliminates multiple incubators, environments and storage
  • Enables implementation of STEC recommendations
  • Improves accuracy, efficiency and time to results with molecular technology
  • CE-IVD


 
BD MAX™ C Difficile     BD MAX™ C Difficile

 

 

Related Documents

 

 

True walkaway automation to

improve diagnosis and treatment of

Clostridium difficile infections (CDI)

Clostridium difficile infections (CDI) have increased substantially in the last decade and continue to challenge clinicians, epidemiologists, and microbiologists. 15-25% of cases of antibiotic-associated diarrhea and over 95% of cases of antibiotic-associated pseudomembranous colitis are caused by CDIs,1 resulting in over $1 billion in excess health care costs annually.2

Nucleic acid amplification tests provide better sensitivity over enzyme immunoassay (EIA) and glutamate dehydrogenase (GDH) testing algorithms and are easier to perform compared to toxigenic culture.3,4

The BD MAX™ Cdiff assay delivers accurate and timely results which enable appropriate treatment and infection control measures to be implemented which helps improve patient outcomes, potentially reduce hospital costs, and increase patient satisfaction.5

The BD MAX™ System is a fully automated sample-to-result platform that provides unique versatility, enabling you to consolidate and standardize your molecular testing.

With up to 24 results in < 3 hours, BD MAX™ can be easily integrated into your routine laboratory workflow.

1 Bartlett JG et al, CID 46(Suppl 1):S12-S18.

2 Dubberke ER, et al, CID 2008;46:497–504.

3 Cohen SH, et al, ICHE 2010;31:431–55.

4 Swindells J,et al, J Clin Microbiol 2010;48:606–8.

5 M. Catanzaro, AJIC January 2012.

6 Lyras D, et al, Nature 458:1176-9.

 



 
Introducing BD MAX™ MRSA XT with eXTended Detection Technology     Introducing BD MAX™ MRSA XT with eXTended Detection Technology

 

 

Related Documents

The Answer You Need Today From a Single Test Result

 

The BD MAX™ MRSA XT Assay with eXTended Detection Technology accurately identifies:

  • mecA dropouts
  • New MREJ types
  • MRSA strains with the novel mecC gene

 

Reduces the risk of transmission due to new and emerging strains of MRSA
- MRSA strains with the novel mecC gene account for 3 to 4% of all cases 1
- Detection of new MREJ types missed by other assays 2

Avoids cost and patient impact associated with unnecessary isolation and treatment due to mecA dropouts
- Up to 18% of positive MRSA results reported by other molecular assays may actually be false positives 3, 4, 5
- Patients wrongly identified as carriers may acquire MRSA when cohorted with true carriers 5

 

Simple and efficient workflow

Results in about 2 hours, compared to 2-4 days with culture.

You can combine BD MAX™ MRSA XT testing with other assays, in the same run. For example BD MAX™ StaphSR, BD MAX™ Cdiff, and user defined protocols.


1. Data on File
2. Petersen et al., Epidemiology of methicillin-resistant Staphylococcus aureus carrying the novel mecC gene in Denmark corroborates a zoonotic reservoir with transmission to humans Clin Micro Infect 2013; 19:E16-E22
3. Arbefeville et al. Prevalence and Genetic Relatedness of Methicillin-Susceptible Staphylococcus aureus Isolates Detected by the Xpert MRSA Nasal Assay J. Clin. Microbiol. 2011; 49:2996-2999
4. Blanc et al., High Proportion of Wrongly Identified Methicillin-Resistant Staphylococcus aureus Carriers by Use of a Rapid Commercial PCR Assay Due to Presence of Staphylococcal Cassette Chromosome Element Lacking the mecA Gene J. Clin. Microbiol. 2011; 49:722-724
5. Farley et al., Comparison of the BD GeneOhm Methicillin-Resistant Staphylococcus aureus (MRSA) PCR Assay to Culture by Use of BBL CHROMagar MRSA for Detection of MRSA in Nasal Surveillance Cultures from an At-Risk Community Population J. Clin. Microbiol. 2008; 46:743-746